TAFECTA

Tafecta is the 1st global generic of Tenofovir Alafenamide. Tenofovir Alafenamide is an oral nucleoside reverse transcriptase inhibitor (NRTIs).Itis indicated for the treatment of chronic hepatitis b virus (HBV) infection in adults with compensated liver disease.

INDICATIONS AND USAGE

Tafecta is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.

MECHANISM OF ACTION

Mechanism of Action Tenofovir alafenamide is a phosphonamidate prodrug of tenofovir (2’-deoxyadenosine monophosphate analog). Tenofovir alafenamide as a lipophilic cell-permeant compound enters primary hepatocytes by passive diffusion and by the hepatic uptake transporters OATP1B1 and OATP1B3. Tenofovir alafenamide is then converted to tenofovir through hydrolysis primarily by carboxylesterase 1 (CES1) in primary hepatocytes.

Intracellular tenofovir is subsequently phosphorylated by cellular kinases to the pharmacologically active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits HBV replication through incorporation into viral DNA by the HBV reverse transcriptase, which results in DNA chain-termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase γ and there is no evidence of toxicity to mitochondria in cell culture.

HOW DOES IT WORK IN HBV ?

The active substance in Tafecta,tenofovir alafenamide, works by stopping the hepatitis B virus in the
liver from multiplying.

It is converted in the body into its active compound tenofovir, which blocks the
activity of reverse transcriptase, an enzyme made by the hepatitis B virus that allows it to reproduce
itself in the cells it has infected.